Latest Major R&D Pipeline

Major R&D Pipeline

As of November 8, 2024
(Updated based on quarterly financial disclosure)

  • ●:Development progress from July 2024 onwards  ○:Development progress from April 2024 onwards

Neurology

Dementia

*You can scroll to the left or right here

 
DiseaseStudyRegionDevelopment Stage
「Leqembi」(lecanemab/BAN2401) Treatment for Alzheimer’s disease (AD)/ anti-Aβ protofibril antibody In-license (BioArctic AB) Injection (intravenous infusion, subcutaneous injection) Joint development with Biogen Inc.
Early AD 301 (Clarity AD) Asia (South Korea) Approval (April 2024)
Great Britain Approval (August 2024)
Europe Submission
(accepted: January 2023)
IV maintenance dosing for early AD (Additional Dosage and Administration) 201/301 US Submission (June 2024)
Maintenance dosing of a subcutaneous injection formulation for early AD (Additional Formulation) 301 US Completion of Rolling Submission (October 2024)
Preclinical AD 303 (AHEAD 3-45) Japan/US/Europe PⅢ
E2814 anti-MTBR tau antibody Collaboration (University College London) Injection
Dominantly inherited AD (in combination with lecanemab) Tau Nexgen JP/US/EU PⅡ/Ⅲ
Dominantly inherited AD 103 US/EU PⅠb/Ⅱ
Sporadic early AD (in combination with lecanemab) 202 JP/US PⅡ
E2511 TrkA integrated synapse regenerant In-house Oral
AD - US PⅠ
E2025 Anti-EphA4 antibody In-house Injection
AD - US PⅠ

Neurological diseases other than dementia

*You can scroll to the left or right here

DiseaseStudyRegionDevelopment Stage
「Fycompa」(perampanel/E2007) Antiepileptic agent / AMPA receptor antagonist In-house Oral / Injection
Adjunctive therapy for primary generalized tonic-clonic seizures (Additional Indication) 332 China Approval (April 2024)
「Dayvigo」(lemborexant/E2006) Insomnia treatment / Orexin receptor antagonist In-house Oral
Insomnia disorder 311 China Submission (accepted: January 2024)
「Rozebalamin」(mecobalamin/E0302) Treatment for Amyotrophic lateral sclerosis (ALS) In-house Injection
ALS JETALS (IIS) Japan Approval (September 2024)
lorcaserin/E2023 Treatment for Dravet syndrome / serotonin 2C receptor agonist In-license (Arena Pharmaceuticals) Oral
Dravet syndrome 304 US PⅢ
E2086 Orexin receptor agonist In-house Oral
Narcolepsy - US PⅠb
EA4017 In-house Oral
Chemotherapy-induced peripheral neuropathy (Development conducted by EA Pharma) - Japan PⅠ

Oncology

※左右にスクロールできます

DiseaseStudyRegionDevelopment Stage
「Lenvima/Kisplyx」(lenvatinib/E7080) Anticancer agent / kinase inhibitor In-house Oral
In combination with anti-PD-1 therapy pembrolizumab, joint development with Merck & Co., Inc., Rahway, NJ, USA, through an affiliate (Additional Indication)
Hepatocellular carcinoma (in combination with transcatheter arterial chemoembolization) / First-line LEAP-012 JP/US/EU/CH PⅢ
Esophageal carcinoma (in combination with chemotherapy) / First-line LEAP-014 JP/US/EU/CH PⅢ
Gastric cancer (in combination with chemotherapy) / First-line LEAP-015 JP/US/EU/CH PⅢ
In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Indication)
Hepatocellular carcinoma - Japan PⅠb
「Halaven」(eribulin/E7389) Anticancer agent / microtubule dynamics inhibitor In-house Injection
Monotherapy (Additional Formulation)
Liposomal formulation - JP/EU PⅠ
In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Formulation)
Liposomal formulation 120 Japan PⅠb/Ⅱ
「Tasfygo」(tasurgratinib/E7090) Anticancer agent / FGFR1, FGFR2, FGFR3 inhibitor In-house Oral
Biliary tract cancer with FGFR2 gene fusion 201 Japan Approval (September 2024)
Breast cancer - Japan PⅠb
farletuzumab ecteribulin(FZEC)/MORAb-202 Anticancer agent / Folate receptor α targeted antibody drug conjugate In-house Injection
Non-small cell lung cancer 203 US/EU PⅡ
Ovarian cancer, peritoneal cancer, fallopian tube cancer 205 JP/US/EU PⅡ
Solid tumors 201 US/EU PⅠ/Ⅱ
BB-1701 Anticancer agent / HER2 targeted antibody drug conjugate In-house Injection
Breast cancer 205 JP/US PⅡ
E7386 Anticancer agent / CBP/β-catenin interaction inhibitor Collaboration (PRISM BioLab) Oral
Solid tumors (in combination with pembrolizumab) 201 JP/US/EU PⅠb/Ⅱ
Solid tumors - JP/US/EU PⅠ
Solid tumors (in combination with lenvatinib) - JP/US/EU PⅠb
H3B-6545 Anticancer agent / ERα inhibitor In-house Oral
Breast cancer (in combination with CDK4/6 inhibitor palbociclib) - US/EU PⅠb
E7130  Anticancer agent Collaboration (Harvard University) Injection
Solid tumors - Japan PⅠ
E7766 Anticancer agent In-house Injection
Solid tumors - US/EU PⅠb

Global Health

※左右にスクロールできます

DiseaseSponsor of studyRegionDevelopment Stage
fosravuconazole/E1224 Antifungal agent / ergosterol synthesis inhibitor In-house Oral
Eumycetoma
*Supported by GHIT fund
*Eisai is mainly responsible for non-clinical studies and the provision of the investigational drug.
DNDi・Mycetoma Research Center of the University of Khartoum Sudan PⅡb/Ⅲ
SJ733 Antimalarial agent / ATP4 inhibitor Co-development (University of Kentucky) Oral
Malaria
*Supported by GHIT fund
*Eisai is responsible for the provision of drug substance and formulation manufacturing
University of Kentucky Peru PⅡ
AWZ1066S Antifilarial agent / antiwolbachia mechanism Co-development (Liverpool School of Tropical Medicine) Oral
Lymphatic filariasis and onchocerciasis (river blindness)
*Supported by the GHIT Fund and Medical Research Council in the UK
*Eisai is responsible for the provision of drug substance and formulation manufacturing
Liverpool School of Tropical Medicine UK PⅠ

Gastrointestinal Disorders

※左右にスクロールできます

DiseaseStudyRegionDevelopment Stage
MOVICOL/(AJG555) Chronic constipation treatment / polyethylene glycol preparation In-license (Norgine) Oral
Chronic constipation in children under 2 years of age (Additional Dosage and Administration) (Development conducted by EA Pharma) CT3 Japan PⅢ
AJM347 In-house Oral
Inflammatory bowel disease (Joint development conducted by EA Pharma with Ensho Therapeutics, Inc) - EU PⅠ
EA1080 In-house Oral
Inflammatory bowel disease (Joint development conducted by EA Pharma with Ensho Therapeutics, Inc) - EU PⅠ
EA3571 In-house Oral
Metabolic dysfunction-associated steatohepatitis (Development conducted by EA Pharma) - Japan PⅠ

Other

※左右にスクロールできます

DiseaseStudyRegionDevelopment Stage
「URECE」(dotinurad / FYU-981) Treatment for Hyperuricemia and Gout / selective URAT1 inhibitor In-license (FUJI YAKUHIN) Oral
Gout, hyperuricemia - Asia (Thailand)

Approval (September 2024)
Gout 301 China Submission (accepted: January 2024)
E6742 Treatment for Systemic lupus erythematosus / TLR 7/8 inhibitor In-house Oral
Systemic lupus erythematosus 101 Japan PⅠ/Ⅱ
E8001 In house Injection
Rejection reaction associated with organ transplantation - Japan PⅠ